By Fineline Cube 
Superluminal Medicines announced on August 14, 2025, a collaboration with Eli Lilly (NYSE: LLY) to advance small molecule therapeutics targeting undisclosed GPCR targets relevant to cardiometabolic diseases and obesity. This strategic partnership leverages Superluminal’s proprietary platform to discover and optimize compounds for these targets.
Collaboration Details
Under the agreement, Superluminal will utilize its platform to discover and optimize small-molecule therapeutics for undisclosed GPCR targets associated with cardiometabolic diseases and obesity. Once Superluminal delivers development candidates meeting predefined criteria, Lilly will gain exclusive rights to develop and commercialize these compounds.
Financial Terms
Superluminal stands to receive up to $1.3 billion under the agreement. This includes upfront and near-term payments, an equity investment, development and commercial milestones, and tiered royalties on net sales. The collaboration underscores Lilly’s commitment to advancing innovative therapeutics in cardiometabolic health.-Fineline Info & Tech